Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: Inter-individual variability of cimetidine absorption

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 7, 2009, Pages 891-899

  Willmann, Stefan ^a   Edginton, Andrea N ^b   Kleine Besten, Marcus ^c   Jantratid, Ekarat ^c   Thelen, Kirstin ^c   Dressman, Jennifer B ^c  

^a BAYER AG   (Germany)

^b UNIVERSITY OF WATERLOO   (Canada)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Dissolution; Inter individual variability; Oral absorption; Physiologically based pharmacokinetic; Whole body modelling

Indexed keywords

CIMETIDINE; EUDRAGIT; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; HUMAN EXPERIMENT; INTESTINE TRANSIT TIME; MALE; NORMAL HUMAN; SIMULATION; STOMACH EMPTYING; AREA UNDER THE CURVE; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; COMPUTER SIMULATION; DELAYED RELEASE FORMULATION; GASTROINTESTINAL TRANSIT; INTESTINE ABSORPTION; ORAL DRUG ADMINISTRATION; TABLET; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CIMETIDINE; COMPUTER SIMULATION; DELAYED-ACTION PREPARATIONS; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; HISTAMINE H2 ANTAGONISTS; HUMANS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; TABLETS; TISSUE DISTRIBUTION;

EID: 85047682052     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.07.0008     Document Type: Article

References (46)

1. Edginton AN et al. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008; 4: 1143-1152.
2. Nestorov I. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2007; 3: 235-249.
3. Theil FP et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 2003; 138: 29-49.
4. Willmann S et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 2007; 34: 401-431.
5. Somogyi A, Gugler R. Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet 1983; 8: 463-495.
6. Jantratid E et al. Feasibility of biowaiver extension to Biopharmaceutics Classification System class III drug products: cimetidine. Clin Pharmacokinet 2006; 45: 385-399.
7. Willmann S et al. PK-Sim: a physiologically based pharmacokinetic 'whole-body' model. Biosilico 2003; 1: 121-124.
8. Willmann S et al. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 2004; 47: 4022-4031.
9. Dressman J et al. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998; 15: 11-22.
10. Galia E et al. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998; 15: 698-705.
11. Bayer Technology Services GmbH (2008) PK-Sim User Manual, Bayer Technology Services GmbH, Leverkusen, Germany.
12. Willmann S et al. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 2005; 1: 159-168.
13. Jantratid E et al. Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. J Pharm Sci 2006; 95: 974-984.
14. Lindenberg M et al. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004; 58: 265-278.
15. Oberle RL, Amidon GL. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm 1987; 15: 529-544.
16. Douglas Pharmaceuticals Ltd (1999). CYTINE Cimetidine data sheet. http://www.medsafe.govt.nz/Profs/Datasheet/c/cytinetab.htm (accessed 1 October 2008).
17. Brener W et al. Regulation of the gastric emptying of glucose. Gastroenterology 1983; 85: 76-82.
18. Davis SS et al. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27: 886-892.
19. Lin HC et al. Inhibition of gastric emptying by acids depends on pH, titratable acidity, and length of intestine exposed to acid. Am J Physiol 1990; 259: G1025-G1030.
20. Ofori-Kwakye K et al. Gamma scintigraphic evaluation of film-coated tablets intended for colonic or biphasic release. Int J Pharm 2004; 270: 307-313.
21. Graff J et al. Gastrointestinal mean transit times in young and middle-aged healthy subjects. Clin Physiol 2001; 21: 253-259.
22. Snyder WS et al. Digestive system. In: International Commission on Radiological Protection. Report of the Task Group on Reference Man, 23rd International Commission on Radiological Protection. Oxford: Pergamon; 1975. pp. 122-151.
23. Wilson JP. Surface area of the small intestine in man. Gut 1967; 8: 618-621.
24. Tortora GJ, Grabowski SR. The digestive system. In: Tortora GJ, Grabowski SR, eds. Principles of Anatomy and Physiology, 10th edn. New York: Wiley; 2003. pp. 851-905.
25. McClean P et al. Surface features of small-intestinal mucosa in childhood diarrheal disorders. J Pediatr Gastroenterol Nutr 1996; 23: 538-546.
26. Phillips AD et al. Microvillous surface area in secondary disaccharidase deficiency. Gut 1980; 21: 44-48.
27. Phillips AD et al. The structure of the enterocyte in relation to its position on the villus in childhood: an electron microscopical study. Histopathology 1979; 3: 117-130.
28. Sinclair TS et al. The microvillus in adult jejunal mucosa - an electron microscopic study. Histopathology 1984; 8: 739-746.
29. Walkenstein SS et al. Bioavailability of cimetidine in man. Gastroenterology 1978; 74: 360-365.
30. Dressman JB et al. Towards quantitative prediction of oral drug absorption. Clin Pharmacokinet 2008; 47: 655-667.
31. Fagerholm U. Prediction of human pharmacokinetics - evaluation of methods for prediction of volume of distribution. J Pharm Pharmacol 2007; 59: 1181-1190.
32. Fagerholm U. Prediction of human pharmacokinetics - gastrointestinal absorption. J Pharm Pharmacol 2007; 59: 905-916.
33. Kobayashi M et al. Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. Int J Pharm 2001; 221: 87-94.
34. Opara J et al. Prediction of pharmacokinetic parameters and the assessment of their variability in bioequivalence studies by artificial neural networks. Pharm Res 1999; 16: 944-948.
35. Jantratid E et al. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res 2008; 25: 1663-1676.
36. Blank K et al. Physiology-based models to simulate gut wall metabolism of nifedipine (poster presentation). In: DPhG Jahrestagung; October 10-13; Erlangen 2007.
37. Bjornsson TD et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 2003; 43: 943-967.
38. Bender W, Brockmeier D. Pharmacokinetic characteristics of roxatidine. J Clin Gastroenterol 1989; 11: S6-S19.
39. Rowland M, Tozer TN. Clinical Pharmacokinetics - Concepts and Applications, 3rd edn. Baltimore: Williams&Wilkins; 1995.
40. Macia MA et al. Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. Int J Clin Pharmacol Ther 1995; 33: 333-339.
41. Marzo A, Reiner V. Open questions on bioequivalence: the case of multiple peak phenomenon. J Pharm Pharmacol 2004; 56: 281-282.
42. Plusquellec Y et al. A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Biopharm 1987; 15: 225-239.
43. Weitschies W et al. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm Res 2005; 22: 728-735.
44. Mummaneni V et al. Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs. Pharm Res 1995; 12: 780-786.
45. Langguth P et al. Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH. Biopharm Drug Dispos 1994; 15: 719-746.
46. Takamatsu N et al. Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility. Eur J Pharm Biopharm 2002; 53: 37-47.